TickerWorth Open the interactive view →

Acadia Pharmaceuticals Inc. (ACAD) — Available-Data Snapshot

Updated Nov 10, 2026 · available-data snapshot · descriptive, not a DCF, not advice

Price
$16.50
Market cap
$2,851,678,208
52-week high
$30.96
52-week low
$15.87
Currency
USD
Exchange
NasdaqGS

We don't publish a discounted-cash-flow fair value for Acadia Pharmaceuticals Inc. (ACAD) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.

On the numbers we do have, ACAD trades at a recent price of $16.50, a market capitalisation of about $2,851,678,208, sitting 4% of the way up its 52-week range ($15.87–$30.96), on the NasdaqGS.

The standard alternative to a DCF is relative valuation — comparing ACAD's trading multiples against a sector benchmark. Here that gives P/E of 10.0× (cheaper than the peer median of 45.8×); Fwd P/E of 15.8× (cheaper than the peer median of 18.1×); P/B of 2.1× (cheaper than the peer median of 8.3×); P/S of 2.4× (cheaper than the peer median of 6.8×); EV/EBITDA of 14.4× (cheaper than the peer median of 18.5×). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.

The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. ACAD shows a price-to-book (P/B) of 2.05 and book value of $8.03 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.

Finally, a price-based read — explicitly not a valuation. ACAD is in a down-trend (price below both its 50- and 200-day averages), trading -46.7% from its 52-week high. Over the past year the stock is -4.4%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.

Relative valuation — ACAD vs peers

MultipleACADPeer median
P/E10.0×45.8×cheaper than
Fwd P/E15.8×18.1×cheaper than
P/B2.1×8.3×cheaper than
P/S2.4×6.8×cheaper than
EV/EBITDA14.4×18.5×cheaper than

Sector benchmark (bellwethers, not direct competitors).

Asset / book-value view

Price / book (P/B)
2.05
Book value / share
$8.03

Price-to-book compares the market price to the accounting net-asset value per share. Most useful for asset-heavy businesses, banks and insurers.

Price-based snapshot

50-day avg
$22.86
200-day avg
$23.54
From 52-wk high
-46.7%
1-year momentum
-4.4%

Price-based, not a valuation. Moving-average trend and 52-week position describe where the stock has traded — they say nothing about fair value.

Explore more

Most undervalued stocks (per our valuation) · All valued stocks · Interactive ACAD view

A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is an educational tool, not a licensed investment adviser. Figures are estimates derived from public market data and can be wrong, stale or incomplete.